VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market capitalization of
VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.
Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain....
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market capitalization of
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment,...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q2 CY2026, with sales up 10.2% year on year to $7.80 billio...
Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and incre
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on yea...
